Top

Reactions Weekly

Published in:

01-08-2023 | Metastasis | Case report

Carboplatin/gemcitabine/sintilimab

Lack of efficacy, myelosuppression and off label use: case report

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Xu T, et al. Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review. Frontiers in Oncology 13: 23 Jun 2023. Available from: URL: http://doi.org/10.3389/fonc.2023.1119343

Title: Carboplatin/gemcitabine/sintilimab
Lack of efficacy, myelosuppression and off label use: case report
Publication date: 01-08-2023
Publisher: Springer International Publishing
Keyword: Metastasis
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-44251-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Carboplatin/gemcitabine/sintilimab

Lack of efficacy, myelosuppression and off label use: case report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Multiple drugs

Norepinephrine

Sotrovimab

Tozinameran

Glucose/naloxone/sodium-valproate

Ibrutinib